Autologous Bone Marrow Transplant with CC/MCC DRG Reimbursement

DRG 016 encompasses autologous bone marrow transplant admissions with Major Complication or Comorbidity and represents high-acuity transplant care important to inpatient reimbursement. Accurate assignment affects Medicare payment because the Diagnosis-Related Group groups cases by clinical complexity and expected resource utilization.

DRG 016 Overview

DRG 016 covers inpatient admissions for autologous bone marrow transplant procedures with at least one Major Complication or Comorbidity present. This Diagnosis-Related Group captures higher resource use tied to complex transplant care, including stem cell harvesting, conditioning regimens, and management of transplant-related complications. It matters for Medicare payment because higher severity assignments result in increased prospective reimbursement to reflect the intensified inpatient services and prolonged resource consumption.

DRG 016 Overview

Trials evaluating peri-transplant infection prevention strategies: studies focus on interventions to reduce bacterial, viral, and fungal infections during the neutropenic period surrounding autologous bone marrow transplant (conditioning through engraftment). Typical populations are adults receiving high-dose chemotherapy followed by autologous grafts for hematologic malignancies (e.g., multiple myeloma, lymphoma) who experience prolonged neutropenia and mucosal barrier injury. This research is relevant to providers and payers because infection-related complications drive intensive resource use, lengthen stays, and increase costs and readmissions in this DRG, so evidence on effective prophylaxis or early diagnostics can alter inpatient utilization and reimbursement risk.
Comparative effectiveness studies of conditioning regimens and graft processing methods: randomized or observational studies compare different high-dose chemotherapy protocols, stem cell mobilization approaches, or ex vivo graft manipulations that influence toxicity, time-to-engraftment, and short-term complications. Patient cohorts include candidates for autologous transplant stratified by disease (e.g., relapsed/refractory lymphoma vs newly diagnosed multiple myeloma), comorbidity burden, and age, with outcomes emphasizing transplant-related organ toxicity, transfusion needs, and length of hospitalization. These trials inform clinicians and payers about which protocols minimize severe complications and CC/MCC-level events, thereby impacting DRG cost drivers, case mix adjustments, and clinical pathways used to manage resource intensity.
Post-discharge outcomes and value-based care studies: longitudinal observational studies or pragmatic trials examine readmission rates, outpatient supportive care needs, quality of life, and long-term survivorship outcomes after discharge from the index transplant admission. Populations include survivors of autologous transplant during the first 100 days post-transplant, with analyses of predictors for early readmission, outpatient infusion utilization, and hospice or palliative service use. For providers and payers, this research highlights opportunities to reduce costly readmissions and optimize transitions of care, which can lower total episode spending and improve performance on bundled payments and quality metrics associated with this DRG.

Trials evaluating peri-transplant infection prevention strategies: studies focus on interventions to reduce bacterial, viral, and fungal infections during the neutropenic period surrounding autologous bone marrow transplant (conditioning through engraftment). Typical populations are adults receiving high-dose chemotherapy followed by autologous grafts for hematologic malignancies (e.g., multiple myeloma, lymphoma) who experience prolonged neutropenia and mucosal barrier injury. This research is relevant to providers and payers because infection-related complications drive intensive resource use, lengthen stays, and increase costs and readmissions in this DRG, so evidence on effective prophylaxis or early diagnostics can alter inpatient utilization and reimbursement risk.
Comparative effectiveness studies of conditioning regimens and graft processing methods: randomized or observational studies compare different high-dose chemotherapy protocols, stem cell mobilization approaches, or ex vivo graft manipulations that influence toxicity, time-to-engraftment, and short-term complications. Patient cohorts include candidates for autologous transplant stratified by disease (e.g., relapsed/refractory lymphoma vs newly diagnosed multiple myeloma), comorbidity burden, and age, with outcomes emphasizing transplant-related organ toxicity, transfusion needs, and length of hospitalization. These trials inform clinicians and payers about which protocols minimize severe complications and CC/MCC-level events, thereby impacting DRG cost drivers, case mix adjustments, and clinical pathways used to manage resource intensity.
Post-discharge outcomes and value-based care studies: longitudinal observational studies or pragmatic trials examine readmission rates, outpatient supportive care needs, quality of life, and long-term survivorship outcomes after discharge from the index transplant admission. Populations include survivors of autologous transplant during the first 100 days post-transplant, with analyses of predictors for early readmission, outpatient infusion utilization, and hospice or palliative service use. For providers and payers, this research highlights opportunities to reduce costly readmissions and optimize transitions of care, which can lower total episode spending and improve performance on bundled payments and quality metrics associated with this DRG.

OpenPayer

Autologous Bone Marrow Transplant with CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 016 policy alerts

DRG 016 Overview

OpenPayer

Autologous Bone Marrow Transplant with CC/MCC: Inpatient Reimbursement Overview

Sign up for drg 016 policy alerts

DRG 016 Overview

Clinical Trials

Related Codes

References

Clinical Trials

Related Codes

References